Holen Sie sich die Stockscreener-App
17.10
3.88%
-0.69
Handel nachbörslich:
17.00
-0.10
-0.58%
Schlusskurs vom Vortag:
$17.79
Offen:
$17.82
24-Stunden-Volumen:
9.86M
Relative Volume:
2.60
Marktkapitalisierung:
$1.81B
Einnahmen:
$2.18B
Nettoeinkommen (Verlust:
$-64.32M
KGV:
-17.74
EPS:
-0.9641
Netto-Cashflow:
$91.18M
1W Leistung:
-4.20%
1M Leistung:
-13.46%
6M Leistung:
-19.23%
1J Leistung:
-26.74%
1-Tages-Spanne:
$16.85
$17.84
1-Wochen-Bereich:
$16.37
$18.14
52-Wochen-Spanne:
$14.68
$24.68
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
17.10 | 1.81B | 2.18B | -64.32M | 91.18M | -0.9641 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-07-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2026-01-28 | Fortgesetzt | Barclays | Equal Weight |
| 2025-12-09 | Eingeleitet | Wedbush | Outperform |
| 2025-11-05 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-09-22 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-07-29 | Bestätigt | H.C. Wainwright | Sell |
| 2025-07-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Eingeleitet | Citigroup | Sell |
| 2025-07-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Herabstufung | Mizuho | Outperform → Neutral |
| 2025-07-21 | Herabstufung | Needham | Hold → Underperform |
| 2025-07-21 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-18 | Herabstufung | Needham | Buy → Hold |
| 2025-06-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-06-17 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
| 2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-11-27 | Bestätigt | Needham | Buy |
| 2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
| 2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Eingeleitet | Jefferies | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-12-13 | Fortgesetzt | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-21 | Eingeleitet | Wedbush | Outperform |
| 2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-04 | Eingeleitet | Citigroup | Buy |
| 2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Bestätigt | BTIG Research | Buy |
| 2022-12-16 | Hochstufung | UBS | Neutral → Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Bestätigt | Needham | Buy |
| 2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-01-11 | Herabstufung | UBS | Buy → Neutral |
| 2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Eingeleitet | Mizuho | Buy |
| 2019-11-01 | Eingeleitet | Guggenheim | Buy |
| 2019-08-21 | Bestätigt | Needham | Buy |
| 2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
| 2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-10-12 | Eingeleitet | Bernstein | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
| 2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
| 2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
| 2018-06-20 | Bestätigt | Needham | Buy |
| 2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Top Research Reports for SpaceX, Dell & KLA Corp. - Zacks Investment Research
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
A treatment was linked to better movement over 2 years in boys ages 8 to 12 with Duchenne - Stock Titan
LB Pharmaceuticals Inc (LBRX) Stock Price & News - Syfe
Neurogene Inc. (NGNE) Stock Price & News - Syfe
Sarepta Therapeutics, Inc.Common Stock (NQ: SRPT - The Chronicle-Journal
Sarepta Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet
Sarepta Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet
SRPT Looks 79.1% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Sarepta Therapeutics climbs 10%, rebounding from recent slide (SRPT:NASDAQ) - Seeking Alpha
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High - Benzinga
IRWD Stock Price, Quote & News - Syfe
H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target By Investing.com - Investing.com Canada
AQST Stock Price, Quote & News - Syfe
Sarepta (NASDAQ: SRPT) CFO now holds 121,792 shares after tax withholding - Stock Titan
Tax on stock award trims Sarepta (NASDAQ: SRPT) EVP stake to 115,519 shares - Stock Titan
Sarepta (SRPT) COO reports tax share withholding after RSU vesting - Stock Titan
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook By Investing.com - Investing.com South Africa
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook By Investing.com - Investing.com Canada
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook - Investing.com India
Jefferies reiterates Sarepta Therapeutics stock rating on trial data outlook By Investing.com - Investing.com UK
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower - Benzinga
Mizuho reiterates Sarepta stock rating after Novartis trial miss By Investing.com - Investing.com South Africa
Mizuho reiterates Sarepta stock rating after Novartis trial miss By Investing.com - Investing.com Nigeria
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Yahoo Finance
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year - BioSpace
Why is Sarepta Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Why is Sarepta Therapeutics stock sliding today? By Investing.com - Investing.com India
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year - Business Wire
Why is Sarepta Therapeutics stock sliding today? - Investing.com
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Novartis drops 13% on trial failure, dragging Dyne and Sarepta (NVS:NYSE) - Seeking Alpha
Sarepta Therapeutics (SRPT) Stock Analysis: Navigating the Biotech Landscape with Innovative Therapies - DirectorsTalk Interviews
Sarepta Therapeutics Faces Investor Investigations – 8-5 - stl.news
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report? - Yahoo Finance
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - finance.yahoo.com
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Potential Upside In Biotech Amidst Revenue Challenges - DirectorsTalk Interviews
Sarepta Therapeutics (SRPT) Could Be 30% Undervalued After Elevidys Progress Hopes - Sahm
CytomX Therapeutics, Inc. (CTMX) Stock Price & News - Syfe
Sarepta Therapeutics (SRPT) Could Be 30% Undervalued After Elevidys Progress Hopes - simplywall.st
Sarepta: A Prove-It Story Now Defined By ELEVIDYS Execution - Seeking Alpha
SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’ - Stocktwits
Sarepta (SRPT) Stock Looks Fully Valued As Sales Trail Fair Value - Yahoo Finance
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc.SRPT - Business Wire
Sarepta Therapeutics (NASDAQ:SRPT) Shares Up 9.2%Here's Why - MarketBeat
Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline - Streetwise Reports
Sarepta Therapeutics Jumps 8.6% Amid Sector-Wide Rally - AlphaStreet
Sarepta Therapeutics Delivers Q2 Operating Profit as CEO Transition Advances Pipeline - Streetwise Reports
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sarepta Therapeutics Inc-Aktie (SRPT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| STEPHEN MAYO | Director |
Mar 12 '26 |
Proposed Sale |
17.02 |
7,239 |
123,175 |
0 |
| Estepan Ian Michael | Chief Operating Officer |
Feb 26 '26 |
Option Exercise |
13.71 |
7,450 |
102,140 |
200,750 |
| Nicaise Claude | Director |
Jan 29 '26 |
Option Exercise |
13.71 |
10,500 |
143,955 |
38,312 |
| BEHRENS M KATHLEEN | Director |
Jan 27 '26 |
Option Exercise |
13.71 |
10,500 |
143,955 |
203,976 |
| Estepan Ian Michael | Chief Operating Officer |
Dec 16 '25 |
Sale |
22.31 |
13,187 |
294,202 |
193,300 |
| IAN M ESTEPAN | Officer |
Dec 16 '25 |
Proposed Sale |
22.31 |
13,187 |
294,145 |
0 |
2.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):